| 27.79 -0.29 (-1.03%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 39.49  |
1-year : | 44.01 |
| Resists | First : | 33.81 |
Second : | 37.68 |
| Pivot price | 31.03 |
|||
| Supports | First : | 27.54 | Second : | 22.92 |
| MAs | MA(5) : | 28.81 |
MA(20) : | 31.47 |
| MA(100) : | 22.5  |
MA(250) : | 17.59 |
|
| MACD | MACD : | -0.6 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 6.3 |
D(3) : | 8.5 |
| RSI | RSI(14): 37 |
|||
| 52-week | High : | 41.13 | Low : | 10.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AMLX ] has closed above bottom band by 9.7%. Bollinger Bands are 9.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.85 - 29.05 | 29.05 - 29.21 |
| Low: | 27.12 - 27.39 | 27.39 - 27.6 |
| Close: | 27.42 - 27.78 | 27.78 - 28.06 |
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Sun, 04 Oct 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wed, 23 Sep 2026
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum - Business Wire
Wed, 19 Aug 2026
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock - Business Wire
Tue, 18 Aug 2026
Why Amylyx Pharmaceuticals Stock Skyrocketed Today - The Motley Fool
Mon, 17 Aug 2026
Amylyx Pharmaceuticals Stock Soars After the Close: Here's Why - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 128 (M) |
| Shares Float | 97 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 94.1 (%) |
| Shares Short | 13,510 (K) |
| Shares Short P.Month | 13,430 (K) |
| EPS | -1.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -44.2 % |
| Return on Equity (ttm) | -74.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.73 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -127 (M) |
| Levered Free Cash Flow | -77 (M) |
| PE Ratio | -19.71 |
| PEG Ratio | 0 |
| Price to Book value | 12.92 |
| Price to Sales | 0 |
| Price to Cash Flow | -28.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|